Preview

Rational Pharmacotherapy in Cardiology

Advanced search

REMODELING OF THE RIGHT HEART AND THE LEVEL OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A COMPARATIVE CROSS-SECTIONAL OBSERVATIONAL STUDY

https://doi.org/10.20996/1819-6446-2013-9-3-258-264

Full Text:

Abstract

Aim. To study the right heart remodeling and level of N-terminal brain natriuretic peptide (Nt-proBNP) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Material and methods. Patients (n=79) after pulmonary embolism were included into the study. The main group consisted of patients (n=43) with an increase in systolic pulmonary artery pressure (SPAP) >30 mm Hg: 30 (37.9%)  patients had pulmonary hypertension (PH) degree I, and 13 (16.5%)  — PH degree II–III. Group of comparison con- sisted of 36 patients expired pulmonary embolism and having SPAP <30 mm Hg. The control group consisted of 20 people. 6-minute walk test (6-MWT) and Doppler echocardiography were performed in all patients. Besides myocardial tissue Doppler echocardiography and assessment of Nt-proBNP level were performed in 38 and 71 patients, respectively. Results. Dyspnea occurred in 90.7% of patients with various degrees of PH and 80.5% of patients with normal SPAP. Patients without PH and with PH I complained of palpitations, weakness, fatigue, and dizziness with similar frequency. Patients with PH I were comparable with ones of comparison group in 6-MWT distance that dramatically decreased in patients with PH II–III. Enlargement of the right atrium (RA) and/or right ventricular (RV) was observed in 76.7% of patients with PH I and 100% of patients with PH II–III. RV diastolic function abnormalities (E/A<1 and E/A>2) were detected in 19.4%, 16.7% and 61.5% of patients of comparison group, PH I and PH II–III patients, respectively. According to myocardial tissue Doppler echocardiography Em/Am<1 was observed in 8 (72.7%) patients of the comparison group and in 13 (76.4%) patients with PH. Nt-proB-NP level was 17.3 [2.3, 33.9] fmol/ml in PH I patients and 142.1 [62.1, 171.8] fmol/ml in PH II–III patients. Nt-proBNP level was 6.5 [3.1, 18.3] fmol/mL in patients of the comparison group, and it was higher than this in patients of the control group (3.5 [1.8, 7.5 fmol/ml]. Conclusion. Various indicators of heart remodeling and RV diastolic dysfunction were found in the majority of patients after pulmonary embolism, including those with nor- mal SPAP. Elevation of Nt-proBNP level adequately reflects the severity of RV dysfunction in CTEPH patients only in PH II–III. This marker has low diagnostic value in patients with- out CTEPH and PH I patients.

About the Authors

A. A. Klimenko
Pirogov Russian National Research Medical University, Moscow
Russian Federation


N. A. Shostak
Pirogov Russian National Research Medical University, Moscow
Russian Federation


N. A. Demidova
Pirogov Russian National Research Medical University, Moscow
Russian Federation


I. V. Novikov
Pirogov Russian National Research Medical University, Moscow
Russian Federation


S. M. Sorokoletov
Pirogov Russian National Research Medical University, Moscow; N.I. Pirogov City Clinical Hospital № 1, Moscow
Russian Federation


S. V. Madoyan
City Clinical Hospital № 13, Moscow
Russian Federation


References

1. Lang I.M. Chronic thromboembolic pulmonary hypertension – not so rare after all. N Engl J Med

2. ;350(22):2236–2238.

3. Lang I.M, Klepetko W. Update on chronic thromboembolic pulmonary hypertension, a frequently un- diagnosed condition. Rev Esp Cardiol 2009;62(2):120–125.

4. Tapson V.F., Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006;3(7):564–567.

5. Fedullo P.F., Kerr K.M., et al. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit CareMed 2011;183(12):1605–1613.

6. Hoeper M.M., Mayer E., Simonneau G., Rubin L.J. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113(16):2011–2020.

7. Serafini O., Greco F., Misuraca G. et al. Echocardiography in the diagnostic and prognostic evaluation of thromboembolic pulmonary hypertension. Monaldi Arch Chest Dis 2005;64(2):116–123.

8. Caso P., Galderisi M., Cicala S. et al. Association between myocardial right ventricular relaxation time and pulmonary arterial pressure in chronic obstructive lung disease: analysis by pulsed Doppler tissue imaging. J Am Soc Echocardiogr 2001;14(10):970–977.

9. Lindqvist P., Caidahl K., Neuman-Andersen G. et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest 2005;128(2):755–763.

10. Rydman R., Larsen F., Caidahl K., Alam M. Right ventricular function in patients with pulmonary embolism: early and late findings using Doppler tissue imaging. J Am Soc Echocardiogr 2010;23(5): 531–537.

11. Vonk-Noordegraaf A., Marcus J.T., Gan C.T. et al. Interventricular mechanical asynchrony due to right ventricular pressure overload in

12. pulmonary hypertension plays an important role in impaired left ventricular filling. Chest 2005;128 (Suppl 6):628S–630S.

13. Denault A.Y., Couture P., Buithieu J. et al. Left and right ventricular diastolic dysfunction as predictors of difficult separation from cardiopulmonary bypass. Can J Anaest 2006;53(10):1020–1029.

14. Silver M.A., Maisel A., Yancy C.W. et al. BNP Consensus Panel 2004: A clinical approach for the di- agnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10 (5 Suppl 3):1–30.

15. Galiè N., Hoeper M.M., Humbert M., et al.; ESC Committee for Practice Guidelines (CPG). Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. The Task Force for the Diagnosis and Treat- ment of Pulmonary Hypertension of the European Society of Cardiology and the European Respira- tory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J 2009;30:2493–2537.

16. Nagaya N., Ando M., Oya H. et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002;74(1):180–184.

17. Reesink H.J., Tulevski I.I., Marcus J.T. et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84(2):537–543.

18. Bonderman D., Wexberg P., Martischnig A.M. et al. A non-invasive algorithm to exclude precapillary pulmonary hypertension. Eur Respir J 2011;37(5):1096–1103.

19. Dentali F., Donadini M., Gianni M. et al. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med 2009;4(2):123–128.

20. Casserly B., Klinger J.R. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009;3:269–287.

21. Suntharalingam J., Goldsmith K., Toshner M. et al. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med 2007;101(11):2254–2262.

22. Rybakov MK, Alekhin MN, Mitkov VV. Practical guide to ultrasound. Echocardiography. Moscow: Vidar-M; 2008. Russian (Рыбакова М.К., Алехин М.Н., Митьков В.В. Практическое руководство по ультразвуковой диагностике. Эхокардиография. М.: Видар-М; 2008).

23. National guidelines for the diagnosis and treatment of chronic heart failure. Heart Failure 2010; 11 (1): 1–45. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности. Сердечная недостаточность 2010; 11 (1): 1–45).

24. Vieillard-Baron A., Page B., Augarde R. et al. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med 2001;27(9):1481–1486.

25. Ryan T., Petrovic O., Dillon J.C. et al. An echocardiographic index for separation of right ven-tricular volume and pressure overload. J Am Coll Cardiol 1985;5(4):918–927.

26. Pengo V., Lensing A.W., Prins M.H. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350(22):2257–2264.

27. Saveliev VS, editor. Phlebology: A Guide for Physicians. Moscow: Medicine; 2001. Russian (Савельев В.С., редактор. Флебология: Руководство для врачей. М.: Медицина; 2001).

28. Sutton M.G., Oldershaw P.J. Textbook of adult and pediatric echocardiography and Doppler. Boston: Blackwell Scientific Publications; 1989.

29. Ribeiro A, Lindmarker P, Johnsson H et al Pulmonary embolism. One-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999;99(10):1325–1330.

30. Blanchard D.G., Malouf P.J., Gurudevan S.V. et al. Utility of right ventricular Tei index in the noninvasive evaluation of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy. JACC Cardiovasc Imaging 2009;2(2):143–149.


For citation:


Klimenko A.A., Shostak N.A., Demidova N.A., Novikov I.V., Sorokoletov S.M., Madoyan S.V. REMODELING OF THE RIGHT HEART AND THE LEVEL OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: A COMPARATIVE CROSS-SECTIONAL OBSERVATIONAL STUDY. Rational Pharmacotherapy in Cardiology. 2013;9(3):258-264. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-258-264

Views: 738


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)